Levy C

Language: English
References: 7
Page: 704-706
PDF size: 104.44 Kb.

ABSTRACT

Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-line drug. Evidence is building up in favor of fibrates, which are available for off-label use.

REFERENCES

1. Floreani A, Tanaka A, Bowlus C, Gershwin ME. Geoepidemiology and changing mortality in primary biliary cholangitis. J Gastroenterol 2017; 52: 655-62.

2. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375: 631-43.

3. Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, et al. Cost-Effectiveness of Pre versus Post Liver Transplant Hepatitis C Treatment with Direct-Acting Antivirals. Clin Gastroenterol Hepatol 2017.

4. Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology 2015; 62: 635-43.

5. Cuperus FJ, Halilbasic E, Trauner M. Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol 2014; 30: 279-86.

6. Corpechot C, Chazouilleres O, Rousseau A, Guyader D, Habersetzer F, Mathurin P, et al. A 2-year multicentre, double- blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid (Bezurso). Journal of Hepatology 2017; 66 (1): S89.

7. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147(6): 1338-49.e5; quiz e15.